Long-Term Response to Single-Agent Lenalidomide in an Elderly Patient with Relapsed Hepatosplenic T-Cell Lymphoma

Although data on HSTCL are limited, the nearly two-year CR achieved with single-agent lenalidomide in our case-despite poor prognostic factors like advanced age, bone marrow involvement and relapsed diseasehighlights its potential efficacy.This supports lenalidomide as a viable option in aggressive lymphoma subtypes like HSTCL, especially for patients ineligible for intensive therapy.The low incidence of the disease limits robust trial data and complicates the evaluation of treatment efficacy in broader populations.In conclusion, this case highlights the potential of lenalidomide as a promising option for HSTCL, particularly in situations where standard treatments cannot be administered or are contraindicated.